Figure 5

(A) HepG2 cells were treated for 24 h with 0–200 μM RES; CAV1, MAPKs, and caspase-3 protein levels were further determined by Western blot. (B) – HepG2 variants were treated with 200 μM RES for 24 h; CAV-1, caspase-3 and MAPKs protein levels were determined by Western blot. (C) – HepG2 variants were pre-treated for 30 minutes with or without 20 μM of the P38 inhibitor SB203580 prior to the 24 h treatment with 200 μM RES; CAV1, caspase-3 and MAPKs protein levels were determined by Western blot. Experiments were repeated 3 times, with similar results.